Microdosing GLP-1: What the Term Means and What the Evidence Shows

“Microdosing” a GLP-1 means using a dose below the labelled therapeutic range — often well below the lowest step on the titration schedule. The term is borrowed loosely from other contexts and has no regulatory or pharmacological definition here.

What the labelled schedules actually are

Both drugs are labelled with a stepped titration towards a maintenance dose. The steps are not arbitrary — they exist because gastrointestinal tolerability depends heavily on how quickly the dose rises.

Where the practice came from

Three pressures converged, none of them clinical:

1. Cost. A vial or pen stretched across more weeks costs less per week.

2. Supply. During shortage periods, extending supply was a practical response.

3. Side effects. Gastrointestinal effects are the main reason people stop, and a smaller dose produces fewer of them — which is true and is also true of not taking the drug.

The third is the one worth examining, because it contains a real trade-off rather than a simple economy.

What the trials tested — and did not

Every pivotal trial in this class used a titration schedule towards a target maintenance dose. Efficacy and safety were both measured against that design.

The bottom three rows are the entire microdosing proposition, and nothing tested them. That is not a claim that microdosing fails — it is a statement that the question was never asked in a trial.

The dose-response assumption

Microdosing assumes that a fraction of the dose delivers a fraction of the effect. Dose-response curves in this class are not linear, and there are two distinct reasons the assumption can fail.

• Receptor occupancy is non-linear. Below a threshold of receptor engagement, effect can fall away faster than dose does.

• Some effects have different dose-thresholds than others. Appetite suppression, gastric emptying and glycaemic effects do not necessarily scale together, so a low dose may retain some effects and lose others — not uniformly reduce all of them.

The muscle question does not go away

A recurring argument for microdosing is that slower weight loss protects lean mass. Skeletal muscle health during incretin-based therapy is an active research area, and the concern is real — but it is driven by the rate and magnitude of weight loss and by protein intake and resistance training, not by the dose number itself.

A low dose that produces slow weight loss and a high dose that produces slow weight loss present the same lean-mass picture. The dose is a lever on the rate; it is not independently protective.

Practical problems with dosing below the label

• Pens are not built for it. Dose selectors move in fixed increments, and the volume per increment is not published. See the pen clicks guide.

• Compounded and research vials shift the arithmetic. Concentration is set at reconstitution, so the same “dose” means different things across vials. The reconstitution guide covers this.

• Extending a vial extends its time in use, which runs into the 28-day bacteriostatic water limit regardless of how much peptide remains.

• Nothing measures the result. Trials had endpoints. A low dose used at home has no measurement establishing whether it is doing anything.

What to discuss with a prescriber

1. Whether a slower titration within the labelled range addresses the tolerability problem.

2. Whether staying at a lower labelled step, rather than below the range, is appropriate.

3. What is being measured to tell whether the dose is working.

4. How protein intake and resistance training are being handled alongside any weight loss.

The semaglutide dosage chart and tirzepatide dosage chart set out the labelled schedules, and the semaglutide side effects guide covers what titration is managing.